nipradilol has been researched along with Ventricular Dysfunction, Left in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, M; Sonoki, H; Takeshita, A | 1 |
| Izutani, S; Kim, S; Nakamura, Y; Omura, T; Takeuchi, K; Yoshida, K; Yoshikawa, J; Yoshiyama, M | 1 |
2 other study(ies) available for nipradilol and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Chronic therapy with nipradilol, a beta-adrenergic blocker, attenuated left ventricular remodeling following myocardial infarction in rats.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Cardiac Output; Female; Heart Rate; Myocardial Infarction; Propanolamines; Rats; Rats, Wistar; Ventricular Dysfunction, Left; Ventricular Pressure | 1997 |
Nipradilol can prevent left ventricular systolic and diastolic dysfunction after myocardial infarction in rats.
Topics: Adrenergic beta-Antagonists; Animals; Atrial Natriuretic Factor; Biomarkers; Collagen Type I; Collagen Type III; Disease Models, Animal; Echocardiography, Doppler; Myocardial Infarction; Natriuretic Peptide, Brain; Propanolamines; Rats; Rats, Wistar; RNA, Messenger; Ventricular Dysfunction, Left; Ventricular Remodeling | 2002 |